source
- Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trialLatigo Biotherapeutics said its non-opioid drug reduced acute pain in a Phase 2b study, as the company seeks to compete with Vertex Pharmaceuticals’ approved pain treatment Journavx. Next, Latigo h…Endpoints · 17m ago↗ source
- Apnimed raises $192M IPO for potential 2027 sleep apnea drug launchIn the city that never sleeps, a sleep apnea drug developer has secured a $192 million IPO after more than three years of eyeing a Nasdaq debut. Apnimed is slated to begin ...Endpoints · 22m ago↗ source
- Alnylam shares tumble nearly 30% after cutting revenue outlook for key amyloidosis drugsAlnylam Pharmaceuticals saw its market value drop about 30%, roughly $12 billion, after it lowered its revenue forecast for its leading amyloidosis treatments. The company had previously expected…